A phase I/II trial of weekly nab‐paclitaxel for pretreated non‐small‐cell lung cancer patients without epidermal growth factor receptor mutations and anaplastic lymphoma kinase rearrangement

AIM: We investigated the efficacy, safety and optimal schedule of nanoparticle albumin‐bound paclitaxel monotherapy as second‐ or third‐line treatment for non‐small‐cell lung cancer patients without epidermal growth factor receptor mutation and anaplastic lymphoma kinase rearrangement. METHODS: Pati...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Asia Pac J Clin Oncol
Hlavní autoři: Harada, Daijiro, Kozuki, Toshiyuki, Nogami, Naoyuki, Bessho, Akihiro, Hosokawa, Shinobu, Fukamatsu, Nobuaki, Hotta, Katsuyuki, Ohashi, Kadoaki, Kubo, Toshio, Yoshioka, Hiroshige, Yokoyama, Toshihide, Sone, Naoyuki, Kuyama, Shoichi, Kudo, Kenichiro, Yasugi, Masayuki, Takigawa, Nagio, Oze, Isao, Kiura, Katsuyuki
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2019
Témata:
Original Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6849786/
https://ncbi.nlm.nih.gov/pubmed/30938103
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/ajco.13147
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky